Vanta Bioscience Ltd - 540729 - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
Resignation of Company Secretary w.e.f 10.07.202310-07-2023
10-07-2023
Vanta Bioscience Ltd - 540729 - Announcement under Regulation 30 (LODR)-Meeting Updates
Intimation regarding postponement of Board Meeting dated 30.05.2023 for approval of financial results of the Company30-05-2023
Vanta Bioscience Ltd - 540729 - Board Meeting Intimation for Approval Of Financial Statements For The Period Ended 30.09.2022 And 31.03.2023
Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 ,inter alia, to consider and approve financial statements for the period ended 30.09.2022 and 31.03.202322-05-2023
Vanta Bioscience Ltd - 540729 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyVanta Bioscience Ltd 2CIN NO.L74999TG2016PLC109280 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 13.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: VIDISHA VIMAL HINGU Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: VENKATA SATHYA MURALI DOKKA Designation: CFO EmailId: [email protected] Date: 30/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.30-04-2023
Vanta Bioscience Ltd - 540729 - Compliance Certificate Under Regulation 40(9) Of SEBI (LODR) Regulations, 2015 For The Year Ended March 31, 2023
Compliance Certificate under Regulation 40(9) of SEBI (LODR) Regulations, 2015 for the year ended March 31, 202330-04-2023
Vanta Bioscience Ltd - 540729 - Compliance Certificate Pursuant To Regulation 7(3) Of SEBI (LODR) Regulations For The Year Ended 31.03.2023
Compliance Certificate pursuant to Regulation 7(3) of SEBI (LODR) Regulations for the year ended 31.03.202319-04-2023
Vanta Bioscience Ltd - 540729 - Closure of Trading Window
The trading window for transactions in shares of the Company for all designated persons, their immediate relatives and all concerned will be closed from April 01, 2023 till the end of 48 hours after the declaration of audited financial results of the Company for the half year and year ended March 31, 2023.31-03-2023
Vanta Bioscience Ltd - 540729 - Vayam Research Solutions Limited, Associate Company (Indirect) Of Vanta Bioscience Limited Has Cleared USFDA Audit With Zero 483S
Vayam Research Solutions Limited, Associate Company (indirect) of Vanta Bioscience Limited has cleared USFDA audit with Zero 483s10-03-2023
Vanta Bioscience Ltd - 540729 - Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP)
Settlement with the Operational Creditor - Order of Supreme Court15-02-2023
Vanta Bioscience Ltd - 540729 - Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors
Outcome of the First Meeting of Committee of Creditors of Vanta Bioscience Limited21-01-2023